News Brief: Ogivri and Ziextenzo Now Available in the United States

December 16, 2019

Biosimilars Team

The biosimilars Ogivri (trastuzumab-dkst; Mylan and Biocon) and Ziextenzo (pegfilgrastim-bmez; Sandoz) both have launched in the U.S. market.

Ogivri—a biosimilar to Herceptin (trastuzumab; Genentech, Inc.)—was approved in December 2017 for all eligible indications. It is the second biosimilar Herceptin product available in the United States; Kanjinti (trastuzumab-anns) was marketed in July 2019.

Ogivri is available in a 150 mg single-dose vial and a 420 mg multidose vial. Pricing information was not available.

Ziextenzo—a biosimilar to pegfilgrastim (Neulasta; Amgen)—was approved in November 2019. It joins the already marketed biosimilar pegfilgrastim products Fulphila (pegfilgrastim-jmdb; Mylan) and Udenyca (pegfilgrastim-cbqv; Coherus BioSciences, Inc.).

According to a report from The Center for Biosimilars, the wholesale acquisition cost (WAC) for Ziextenzo is $3925, or an approximate 37% discount off the WAC for Neulasta. This discount is deeper than those initially offered for the competitor biosimilars.